Personalized treatment for recurrent glioblastoma using functional profiling
Individualized Systems Medicine Strategy for Targeting Cancer Stem Cells in Patients With Recurrent Glioblastoma (ISM-GBM)
EARLY_PHASE1 · Oslo University Hospital · NCT05043701
This study is testing a personalized treatment for people with recurrent glioblastoma to see if using their unique cancer profiles can help delay disease progression and improve survival.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Oslo University Hospital (other) |
| Locations | 1 site (Oslo) |
| Trial ID | NCT05043701 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and safety of a personalized cancer stem cell targeted therapy for patients with recurrent glioblastoma. It utilizes high-throughput functional profiling of FDA/EMA-approved drugs to identify effective treatments based on individual patient profiles. The study aims to determine if this approach can safely delay disease progression and improve survival rates. It is a single-center phase 1 study focusing on the practical application of individualized treatment strategies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 with histologically verified recurrent glioblastoma and adequate health status.
Not a fit: Patients currently participating in other clinical trials or those with conditions that preclude participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide more effective and personalized treatment options for patients with recurrent glioblastoma.
How similar studies have performed: There is growing literature supporting the targeting of cancer stem cells to improve therapy outcomes in glioblastoma, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recurrence of histologically verified glioblastoma * Adequate biopsy to generate enough live cells to allow functional screening * Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Must be 18 to 70 years of age * Adequate bone marrow, liver and heart function * Must be competent to give consent * Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Conference on Harmonization Good Clinical Practice guidelines (ICH GCP), and national/local regulations. Exclusion Criteria: * Patients taking part in other clinical trials which could make inclusion or follow-up difficult * Any reason why, in the opinion of the investigator, the patient should not participate
Where this trial is running
Oslo
- Oslo University Hospital — Oslo, Norway (RECRUITING)
Study contacts
- Principal investigator: Einar O. Vik-Mo, MD, PhD — Oslo University Hospital
- Study coordinator: Einar O. Vik-Mo, MD, PhD
- Email: uxvieb@ous-hf.no
- Phone: 23074343
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Recurrent Glioblastoma, functional screening, personalized treatment